-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Effects of palbociclib on mouse ATLL tumors
Gene editing technology has been used to identify new molecular targets for the treatment of aggressive leukemia in adults
Scientists at Hokkaido University have identified a new target for an aggressive form of adult leukemia with existing drugs
Adult T-cell leukemia/lymphoma (ATLL) is a malignant blood cancer associated with viral infection
Masao Nakagawa, a hematologist at Hokkaido University, and his colleagues in Japan, the United States and France used CRISPR-Cas9 gene editing to inactivate thousands of genes in several ATLL cell lines
Among these genes, one gene proved particularly promising as a drug target
The cell lines that were resistant to the drug had mutations in a gene called TP53, which is normally involved in suppressing tumor growth and development
Importantly, the researchers also found that combining palbociclib with everolimus, which is used to treat kidney and breast cancer, also killed ATLL cells, including those with TP53 mutations
"Our study shows that CDK6 is an attractive target for the treatment of ATLL," Nakagawa said
article title
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
